Influence of long-term treatment with glyceryl trinitrate on remote ischemic conditioning

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 315, Issue 1, 2018, Pages H150-H158

  Hauerslev, Marie ^a   Mørk, Sivagowry Rasalingam ^a,b   Pryds, Kasper ^a,b   Contractor, Hussain ^b   Hansen, Jan ^a   Jespersen, Nichlas Riise ^a   Johnsen, Jacob ^a   Heusch, Gerd ^c   Kleinbongard, Petra ^c   Kharbanda, Rajesh ^b   Bøtker, Hans Erik ^a   Schmidt, Michael Rahbek ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cardioprotection; Endothelial function; Glyceryl trinitrate; Ischemic preconditioning; Myocardial infarction; Remote ischemic conditioning

Indexed keywords

GLYCERYL TRINITRATE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; LONG TERM CARE; MALE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; REMOTE ISCHEMIC CONDITIONING; ADOLESCENT; ADULT; ANIMAL; FEMALE; PATHOPHYSIOLOGY; PROCEDURES; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADOLESCENT; ADULT; ANIMALS; ENDOTHELIUM, VASCULAR; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; ISCHEMIC PRECONDITIONING; MALE; MYOCARDIAL REPERFUSION INJURY; NITROGLYCERIN; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 85048707102     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00114.2018     Document Type: Article

References (43)

1. Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, López-Sendón J, Wyman A, Kennelly BM, Fox KA; GRACE Investigators. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 31: 430–438, 2010. doi:10.1093/eurheartj/ehp457.
2. Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727–734, 2010. doi:10.1016/S0140-6736(09)62001-8.
3. Burwell LS, Brookes PS. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid Redox Signal 10: 579–599, 2008. doi:10.1089/ars.2007.1845.
4. Candilio L, Malik A, Ariti C, Barnard M, Di Salvo C, Lawrence D, Hayward M, Yap J, Roberts N, Sheikh A, Kolvekar S, Hausenloy DJ, Yellon DM. Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart 101: 185–192, 2015. doi:10.1136/heartjnl-2014-306178.
5. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998_2010. Circulation 128: 2577–2584, 2013. doi:10.1161/CIRCULATIONAHA.113.003668.
6. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, Kitagawa K, Nakayama KI, Hess DT, Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci USA 102: 12159–12164, 2005. doi:10.1073/pnas.0503723102.
7. Costa AD, Pierre SV, Cohen MV, Downey JM, Garlid KD. cGMP signalling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res 77: 344–352, 2008. doi:10.1093/cvr/cvm050.
8. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 63: 49–63, 2004.
9. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418–458, 2007. doi:10.1124/pr.107.06002.
10. Ferdinandy P, Szilvássy Z, Csont T, Csonka C, Nagy E, Koltai M, Dux L. Nitroglycerin-induced direct protection of the ischaemic myocardium in isolated working hearts of rats with vascular tolerance to nitroglycerin. Br J Pharmacol 115: 1129–1131, 1995. doi:10.1111/j.1476-5381.1995.tb15014.x.
11. Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Luca MC, Thomas G, Oelze M, Daiber A, Parker JD. Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol 298: H340–H345, 2010. doi:10.1152/ajpheart.01324.2008.
12. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion–a target for cardioprotection. Cardiovasc Res 61: 372–385, 2004. doi:10.1016/S0008-6363(03)00533-9.
13. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 1767: 1007–1031, 2007. doi:10.1016/j.bbabio.2007.05.008.
14. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116: 674–699, 2015. doi:10.1161/CIRCRESAHA.116.305348.
15. Heusch G. Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 103: 2876–2878, 2001. doi:10.1161/01.CIR.103.24.2876.
16. Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol 65: 177–195, 2015. doi:10.1016/j.jacc.2014.10.031.
17. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 38: 774–784, 2017. doi:10.1093/eurheartj/ehw224.
18. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383: 1933–1943, 2014. doi:10.1016/S0140-6736(14)60107-0.
19. Hill M, Takano H, Tang XL, Kodani E, Shirk G, Bolli R. Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. Circulation 104: 694–699, 2001. doi:10.1161/hc3201.092218.
20. Jaffe AS, Geltman EM, Tiefenbrunn AJ, Ambos HD, Strauss HD, Sobel BE, Roberts R. Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. Br Heart J 49: 452–460, 1983. doi:10.1136/hrt.49.5.452.
21. Jiang MH, Hada J. Early and sharp nitric oxide production and anoxic depolarization in the rat hippocampus during transient forebrain ischemia. Eur J Pharmacol 567: 83–88, 2007. doi:10.1016/j.ejphar.2007.03.014.
22. Jneid H, Leessar M, Bolli R. Cardiac preconditioning during percutaneous coronary interventions. Cardiovasc Drugs Ther 19: 211–217, 2005. doi:10.1007/s10557-005-2466-8.
23. Johnsen J, Pryds K, Salman R, Løfgren B, Kristiansen SB, Bøtker HE. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol 111: 10, 2016. doi:10.1007/s00395-016-0529-6.
24. Jung C, Gonon AT, Sjöquist PO, Lundberg JO, Pernow J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 85: 147–154, 2010. doi:10.1093/cvr/cvp303.
25. Kevin LG, Camara AK, Riess ML, Novalija E, Stowe DF. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 284: H566–H574, 2003. doi:10.1152/ajpheart.00711.2002.
26. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 106: 2881–2883, 2002.
27. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 103: 1624–1630, 2001. doi:10.1161/01.CIR.103.12.1624.
28. Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E. Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther 27: 359–361, 2013. doi:10.1007/s10557-013-6451-3.
29. Kristiansen SB, Løfgren B, Støttrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Bøtker HE, Flyvbjerg A. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47: 1716–1721, 2004. doi:10.1007/s00125-004-1514-4.
30. Luca MC, Liuni A, McLaughlin K, Gori T, Parker JD. Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study. J Am Heart Assoc 2: e000075, 2013. doi:10.1161/JAHA.112.000075.
31. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7: 156–167, 2008. doi:10.1038/nrd2466.
32. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol 43: 493–499, 1997. doi:10.1046/j.1365-2125.1997.00583.x.
33. Osada M, Takeda S, Sato T, Komori S, Tamura K. The protective effect of preconditioning on reperfusion-induced arrhythmia is lost by treatment with superoxide dismutase. Jpn Circ J 58: 259–263, 1994. doi:10.1253/jcj.58.259.
34. Rassaf T, Ferdinandy P, Schulz R. Nitrite in organ protection. Br J Pharmacol 171: 1–11, 2014. doi:10.1111/bph.12291.
35. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 114: 1601–1610, 2014. doi:10.1161/CIRCRESAHA.114.303822.
36. Shi Y, Hutchins WC, Su J, Siker D, Hogg N, Pritchard KA Jr, Keszler A, Tweddell JS, Baker JE. Delayed cardioprotection with isoflurane: role of reactive oxygen and nitrogen. Am J Physiol Heart Circ Physiol 288: H175–H184, 2005. doi:10.1152/ajpheart.00494.2004.
37. Skyschally A, Amanakis G, Neuhäuser M, Kleinbongard P, Heusch G. Impact of electrical defibrillation on infarct size and no-reflow in pigs subjected to myocardial ischemia-reperfusion without and with ischemic conditioning. Am J Physiol Heart Circ Physiol 313: H871–H878, 2017. doi:10.1152/ajpheart.00293.2017.
38. Steensrud T, Li J, Dai X, Manlhiot C, Kharbanda RK, Tropak M, Redington A. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am J Physiol Heart Circ Physiol 299: H1598–H1603, 2010. doi:10.1152/ajpheart.00396.2010.
39. Swyers T, Redford D, Larson DF. Volatile anesthetic-induced preconditioning. Perfusion 29: 10–15, 2014. doi:10.1177/0267659113503975.
40. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. Cardiovasc Res 28: 980–986, 1994. doi:10.1093/cvr/28.7.980.
41. Whittaker P, Przyklenk K. From ischemic conditioning to ‘hyperconditioning’: clinical phenomenon and basic science opportunity. Dose Response 12: 650–663, 2014. doi:10.2203/dose-response.14-035.Whittaker.
42. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121–1135, 2007. doi:10.1056/NEJMra071667.
43. Zuo L, Roberts WJ, Tolomello RC, Goins AT. Ischemic and hypoxic preconditioning protect cardiac muscles via intracellular ROS signaling. Front Biol 8: 305–311, 2012. doi:10.1007/s11515-012-1225-z.